Ultrashort acting hypnotic barbiturates
AssigneeARYx Therapeutics, Inc.
InventorsPascal Druzgala, Peter G. Milner
Life of this patent
Estimating the term…
Abstract
The subject invention concerns novel compounds that are useful as ultrashort acting hypnotic barbiturates. Specifically exemplified are derivatives of barbituric and thiobarbituric acids. They are rapidly metabolized by blood and tissue enzymes to form polar metabolites with no hypnotic activity and which are rapidly eliminated.
Claims38
A method for providing sedative-hypnotic treatment to an individual in need of such treatment wherein said method comprises administering to the individual an effective amount of a compound, or an analog thereof, wherein said compound has a structure selected from the group consisting of:
- where R1 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R2 and R3 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-4 alkyl, and n is 0 to 5;
- R4 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R6 and R7 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl;
- and
- X1, X2 and X3 are, independently, O, S, or N;
- and
- where R1 is hydrogen, or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R2 and R3 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-4 alkyl, and n is 0 to 5;
- R4 and R5 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R6 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl;
- X1 and X2 are, independently, O, S, or N;
- and
- X3 is S or N.
A method for providing anticonvulsant treatment to an individual in need of such treatment where said method comprises administering to the individual an effective amount of a compound, or an analog thereof, wherein said compound has a structure selected from the group consisting of:
- where R1 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R2 and R3 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-4 alkyl, and n is 0 to 5;
- R4 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R6 and R7 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl;
- and
- X1, X2 and X3 are, independently, O, S, or N;
- and
- where R1 is hydrogen, or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R2 and R3 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-4 alkyl, and n is 0 to 5;
- R4 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R6 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl;
- and
- X1, X2 and X3 are, independently, O, S, or N.
A pharmaceutical composition comprising a compound, or an analog thereof, wherein said compound has a structure selected from the group consisting of:
- where R1 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R2 and R3 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-4 alkyl, and n is 0 to 5;
- R4 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R6 and R7 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl;
- and
- X1, X2 and X3 are, independently, O, S, or N;
- and
- where R1 is hydrogen, or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R2 and R3 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-4 alkyl, and n is 0 to 5;
- R4 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substitutued or unsubstituted) aryl group;
- R6 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl;
- X1 and X2 are, independently, O, S, N;
- and
- X3 is S or N;
- and
- wherein said composition further comprises a pharmaceutically acceptable carrier.
A compound, or an analog thereof, wherein said compound has a structure selected from the group consisting of:
- where R1 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R2 and R3 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-4 alkyl, and n is 0 to 5;
- R4 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R6 and R7 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl;
- and
- X1, X2 and X3 are, independently, O, S, or N;
- and
- where R1 is hydrogen, or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R2 and R3 are, independently, hydrogen or (saturated or unsaturated, branched or unbranched) C1-4 alkyl, and n is 0 to 5;
- R4 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl or a (substituted or unsubstituted) aryl group;
- R6 is hydrogen or (saturated or unsaturated, branched or unbranched) C1-14 alkyl;
- X1 and X2 are, independently, O, S, or N;
- and
- X3 is S or N.
Dependencies are inferred from the claim text.